CA Patent

CA2113995C — Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins

Assigned to Mallinckrodt LLC · Expires 2003-04-22 · 23y expired

What this patent protects

Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol, ascorbic acid, and citrate to inhibit autoradiolysis of radiolabeled pep-tides.

USPTO Abstract

Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol, ascorbic acid, and citrate to inhibit autoradiolysis of radiolabeled pep-tides.

Drugs covered by this patent

Patent Metadata

Patent number: CA2113995C
Jurisdiction: CA
Classification: —
Expires: 2003-04-22
Drug substance claim: No
Drug product claim: No
Assignee: Mallinckrodt LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.